End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
37.54 CNY | -1.57% | -6.48% | -29.56% |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-29.56% | 817M | - | ||
+12.85% | 229B | B | ||
+13.88% | 195B | B- | ||
+18.39% | 142B | B- | ||
+28.78% | 109B | A- | ||
+1.67% | 64.85B | A- | ||
+18.24% | 54.33B | B+ | ||
+7.04% | 52.09B | B+ | ||
+10.83% | 45.15B | A | ||
+5.94% | 37.39B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- 688626 Stock
- Ratings Xiangyu Medical Co.,Ltd